Related Experiment Video

Updated: Jan 20, 2026

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

7.0K

Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A

Kaitlin Haines1, Gloria S Huang2,3

  • 1Department of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine, Yale University, New Haven, Connecticut.

Cancer Research
|August 17, 2019
PubMed

Insights

A common mutation in the PPP2R1A gene drives aggressive endometrial cancers by disrupting protein phosphatase 2A (PP2A) activity. Restoring PP2A function or using a PP2A activator inhibits tumor growth, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Aggressive endometrial cancers, including uterine serous carcinoma and uterine carcinosarcoma, cause over half of endometrial cancer deaths.
  • Approximately one-third of these aggressive cancers have mutations in the PPP2R1A gene, which encodes the protein phosphatase 2A (PP2A) Aα scaffold subunit.

Purpose of the Study:

  • To elucidate the role of the recurrent PPP2R1A P179R mutation as a driver of aggressive endometrial cancer.
  • To investigate therapeutic strategies targeting PP2A activity in endometrial cancer.

Main Methods:

  • Analysis of the structural and functional consequences of the PPP2R1A P179R mutation on PP2A holoenzyme formation and activity.
  • Assessment of tumor growth inhibition by restoring wild-type PPP2R1A or using a small-molecule activator of PP2A (SMAP) in preclinical models.

Main Results:

  • The P179R mutation alters PP2A-Aα protein conformation, leading to impaired holoenzyme formation and reduced phosphatase activity, thereby promoting endometrial cancer progression.
  • Restoration of wild-type PPP2R1A in mutant cells increased phosphatase activity and suppressed tumor growth in vivo.
  • A small-molecule activator of PP2A (SMAP) mimicked the effects of wild-type PPP2R1A restoration, inhibiting tumor growth.

Conclusions:

  • The PPP2R1A P179R mutation is a key biological driver of aggressive endometrial cancer.
  • Targeting PP2A activity through gene restoration or small-molecule activators represents a promising therapeutic avenue for precision treatment of aggressive endometrial cancers.

More Related Videos

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

13.0K
Production and Detection of Reactive Oxygen Species ROS in Cancers07:17

Production and Detection of Reactive Oxygen Species ROS in Cancers

Published on: November 21, 2011

70.9K

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.0K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.4K
Aggression01:47

Aggression

Humans engage in aggression when they seek to cause harm or pain to another person. Aggression takes two forms depending on one’s motives: hostile or instrumental. Hostile aggression is motivated by feelings of anger with intent to cause pain; a fight in a bar with a stranger is an example of hostile aggression. In contrast, instrumental aggression is motivated by achieving a goal and does not necessarily involve intent to cause pain (Berkowitz, 1993); a contract killer who murders for...
30.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K